What are the side effects of cabozantinib?

In clinical studies of cabozantinib (Cabozantinib) in the treatment of renal cell carcinoma, the adverse reactions (≥25%) that occurred were diarrhea, fatigue, nausea, decreased appetite, palmar-plantar paresthesia (PPE), hypertension, vomiting, weight loss and constipation. In clinical studies for the treatment of hepatocellular carcinoma, the adverse reactions (≥25%) that occurred were diarrhea, decreased appetite, PPE, fatigue, nausea, hypertension and vomiting; in the clinical studies of the treatment of differentiated thyroid cancer, the adverse reactions that occurred (≥25%) were diarrhea, PPE, fatigue, hypertension and stomatitis. Adverse events such as aneurysm, dissection, and rupture of arteries (including aorta) have also occurred after cabozantinib was marketed.